Table 3 HEAs (Hit Enriched Assays) from lymphangiogenesis hits

1

Inhibitors of regulator of G protein signaling (RGS) 4

RGS4

9.63

152/390,220

3.40E−16

504,845 (2011)

[38, 39]

2

Validation screen for inhibitors of Lassa infection

–

7.18

54/1279

3.04E−13

463,096 (2010)

3

High content imaging cell-Based qHTS for inhibitors of the mTORC1 signaling pathway in MEF (Tsc2-/-, p53-/-) cells

MTOR

7.12

23/1280

8.03E−09

2666 (2010)

[40, 41]

4

Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells

GMNN

6.77

71/1280

4.61E−11

463,097 (2010)

5

High content imaging cell-based qHTS for inhibitors of the mTORC1 signaling pathway in MEF cells

MTOR

6.35

52/1280

1.85E−10

2667 (2010)

[40, 41]

6

Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1

ATAD5

6.22

79/1280

3.78E−10

493,107 (2011)

7

qHTS assay for identification of small molecule antagonists for thrombopoietin (TPO) signaling pathway

THPO

6.21

122/1277

1.11E−08

918 (2010)

[42, 43]

8

qHTS for inhibitors of ATXN expression: validation

ATXN2

5.94

73/1280

2.67E−07

588,378 (2011)

9

qHTS assay for the inhibitors of human flap endonuclease 1 (FEN1)

FEN1

5.87

1368/391,275

2.04E−07

588,795 (2011)

10

AP1 signaling pathway

AP1

5.85

55/10,692

4.90E−5

357 (2006)

[44, 45]